Through the alliance, the companies will partner on various projects aimed at enhancing the safety and efficacy of CGTs.
This supports the commitment of Labcorp to expand its worldwide, complete suite of CGT expertise while aiding the pharmaceutical and biotechnology companies to accelerate the development of treatments.
CGTs alter the genes of a person for treating diseases by disabling or substituting a disease-causing gene, or through the introduction of a new or modified cell or gene.
These therapies are being analysed to treat various ailments, including Parkinson’s disease, solid tumours, rare diseases, and blood-based malignancies.
The projects that are part of the partnership will leverage the AVATAR incubator system of Xcellbio for developing research-grade CAR-T cell material utilised to destroy cancer cells.
This initiative will aid in showing the importance of knowing the parameters of the tumour microenvironment to create CAR-T cells with enhanced performance.
Furthermore, the technology will be leveraged to adapt cancer cells to more physiologic conditions and extend 3D modelling for in vitro CAR-T testing.
The latest partnership comes after Labcorp made a strategic investment in Xcellbio in November last year.
Labcorp cell and gene therapy enterprise head and vice-president Dr Maryland Franklin said: “Labcorp is firmly committed to helping our clients bring new treatment options to patients in need while revolutionising the future of medicine with cell and gene therapies.
“By pairing the scale and breadth of our enterprise-wide CGT solutions with Xcellbio’s powerful technology, we have an opportunity to enhance and accelerate the CGT development experience.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.